Comparison 6. Mefloquine (MQ) versus sulfadoxine‐pyrimethamine (SP).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
6.1 Maternal peripheral parasitemia at delivery (blood smear)	1	131	Risk Ratio (M‐H, Fixed, 95% CI)	0.70 [0.26, 1.85]
6.2 Placental malaria (blood smear)	1	131	Risk Ratio (M‐H, Fixed, 95% CI)	0.70 [0.12, 4.04]
6.3 Low birth weight (< 2500 g)	1	131	Risk Ratio (M‐H, Fixed, 95% CI)	0.26 [0.03, 2.28]
6.4 Prematurity	1	131	Risk Ratio (M‐H, Fixed, 95% CI)	0.35 [0.07, 1.67]
6.5 Adverse events: nausea	1	131	Risk Ratio (M‐H, Fixed, 95% CI)	8.37 [1.08, 65.08]
6.6 Adverse events: headache	1	131	Risk Ratio (M‐H, Fixed, 95% CI)	0.15 [0.02, 1.18]
6.7 Adverse events: vomiting	1	131	Risk Ratio (M‐H, Fixed, 95% CI)	0.35 [0.01, 8.41]
6.8 Adverse events: dizziness	1	131	Risk Ratio (M‐H, Fixed, 95% CI)	0.42 [0.08, 2.08]
6.9 Adverse events: gastric pain	1	131	Risk Ratio (M‐H, Fixed, 95% CI)	1.05 [0.07, 16.38]